Goldstein Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$630K Sell
525
-1
-0.2% -$1.02K 0.06% 112
2026
Q1
$484K Buy
526
+20
+4% +$20.3K 0.05% 103
2025
Q4
$544K Sell
506
-16
-3% -$15.3K 0.06% 100
2025
Q3
$398K Sell
522
-114
-18% -$84.8K 0.05% 112
2025
Q2
$496K Sell
636
-29
-4% -$22.5K 0.07% 93
2025
Q1
$549K Buy
665
+38
+6% +$31.6K 0.08% 87
2024
Q4
$484K Sell
627
-19
-3% -$15.7K 0.07% 94
2024
Q3
$572K Buy
646
+16
+3% +$14.4K 0.09% 81
2024
Q2
$570K Sell
630
-21
-3% -$16.8K 0.1% 74
2024
Q1
$506K Buy
651
+16
+3% +$11.4K 0.09% 79
2023
Q4
$370K Buy
635
+72
+13% +$42K 0.06% 125
2023
Q3
$302K Buy
563
+32
+6% +$16.5K 0.06% 103
2023
Q2
$249K Buy
+531
New +$223K 0.05% 120
2023
Q1
Sell
-603
Closed -$221K 166
2022
Q4
$221K Buy
+603
New +$214K 0.05% 124

Other funds holding LLY

Goldstein Advisors's LLY Position: Q2 2026 in Review

Goldstein Advisors reduced its Eli Lilly (LLY) stake by 0.19% in Q2 2026, selling an estimated $1.02K and leaving 525 shares worth $630K. The position accounts for 0.06% of the portfolio, ranked #112.

Goldstein Advisors first reported a position in LLY in Q4 2022 and has held it in 14 quarters since. 1,691 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Goldstein Advisors held 525 shares of Eli Lilly worth $630K as of Q2 2026.
  • Goldstein Advisors sold 1 Eli Lilly share in Q2 2026, an estimated $1.02K.
  • Eli Lilly made up 0.06% of Goldstein Advisors's portfolio in Q2 2026, its #112 holding.
  • Goldstein Advisors first reported a position in Eli Lilly in Q4 2022 and has held it in 14 quarters since.
  • 1,691 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Goldstein Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.